Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
暂无分享,去创建一个
Arsène Burny | Dolores Vaira | J. Gatot | A. Burny | C. Van Lint | J. Piette | C. Rouzioux | Y. De Launoit | M. Moutschen | O. Lambotte | K. Kabeya | C. Vanhulle | N. Clumeck | S. De Wit | O. Rohr | G. Herbein | Y. Collette | V. Martinelli | D. Demonté | Stéphane De Wit | Jacques Piette | D. Vaira | Olivier Rohr | Yves Collette | Thomas Cherrier | Allan Guiguen | Nathan Clumeck | Christine Rouzioux | Georges Herbein | Olivier Lambotte | T. Cherrier | Caroline Vanhulle | Kabamba Kabeya | Carine Van Lint | Michel Moutschen | Sophie Reuse | Miriam Calao | Allan Guiguen | Jean-Stéphane Gatot | Vincent Quivy | Aurélia Lamine | Dominique Demonte | Valérie Martinelli | Emmanuelle Veithen | Véronique Avettand | Solène Poutrel | Yvan de Launoit | M. Calao | V. Quivy | E. Veithen | S. Poutrel | S. Reuse | Aurélia Lamine | V. Avettand | D. Demonté
[1] Mahavir Singh,et al. Structural Ramification for Acetyl‐Lysine Recognition by the Bromodomain of Human BRG1 Protein, a Central ATPase of the SWI/SNF Remodeling Complex , 2007, Chembiochem : a European journal of chemical biology.
[2] G. Tunnicliff. Actions of sodium valproate on the central nervous system. , 1999, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[3] C. Van Lint,et al. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. , 2004, Biochemical pharmacology.
[4] E. Verdin,et al. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.
[5] G. Piras,et al. Transcriptional Activation of the Integrated Chromatin-Associated Human Immunodeficiency Virus Type 1 Promoter , 1998, Molecular and Cellular Biology.
[6] R. Bosch,et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression , 2004, AIDS.
[7] M. Vignali,et al. Promoter targeting of chromatin-modifying complexes. , 2001, Frontiers in bioscience : a journal and virtual library.
[8] W. Greene,et al. Prostratin Antagonizes HIV Latency by Activating NF-κB* , 2004, Journal of Biological Chemistry.
[9] R. Siliciano,et al. Experimental approaches to the study of HIV-1 latency , 2007, Nature Reviews Microbiology.
[10] Dimitris Thanos,et al. Ordered Recruitment of Chromatin Modifying and General Transcription Factors to the IFN-β Promoter , 2000, Cell.
[11] Qiang Zhou,et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.
[12] A. Marcello. Latency: the hidden HIV-1 challenge , 2006, Retrovirology.
[13] J. Grivel,et al. Dual Role of Prostratin in Inhibition of Infection and Reactivation of Human Immunodeficiency Virus from Latency in Primary Blood Lymphocytes and Lymphoid Tissue , 2004, Journal of Virology.
[14] Ming-Ming Zhou,et al. Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA , 2008, Molecular and Cellular Biology.
[15] J. Alcamí,et al. Prostratin Induces HIV Activation and Downregulates HIV Receptors in Peripheral Blood Lymphocytes , 2004, Antiviral therapy.
[16] O. Politz,et al. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.
[17] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[18] C. Van Lint,et al. Mutations in the tat Gene Are Responsible for Human Immunodeficiency Virus Type 1 Postintegration Latency in the U1 Cell Line , 1998, Journal of Virology.
[19] W. Greene,et al. Prostratin antagonizes HIV latency by activating NF-kappaB. , 2004, The Journal of biological chemistry.
[20] Mary K. Lewinski,et al. Molecular mechanisms of HIV-1 proviral latency , 2005, Expert review of anti-infective therapy.
[21] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[22] M. Boyd,et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.
[23] D. Olive,et al. The CD2 and CD28 adhesion molecules induce long‐term autocrine proliferation of CD4+ T cells , 1993, European journal of immunology.
[24] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[25] M. Merika,et al. Bypassing the Requirements for Epigenetic Modifications in Gene Transcription by Increasing Enhancer Strength , 2007, Molecular and Cellular Biology.
[26] Anthony S. Fauci,et al. AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.
[27] P. Grant,et al. Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Hamer,et al. Molecular characterization, reactivation, and depletion of latent HIV. , 2003, Immunity.
[29] A. Burny,et al. Potentiation of Tumor Necrosis Factor-Induced NF-κB Activation by Deacetylase Inhibitors Is Associated with a Delayed Cytoplasmic Reappearance of IκBα , 2003, Molecular and Cellular Biology.
[30] C. Van Lint,et al. Transcriptional activation and chromatin remodeling of the HIV‐1 promoter in response to histone acetylation. , 1996, The EMBO journal.
[31] C. Van Lint,et al. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. , 2007, Sub-cellular biochemistry.
[32] J. Brady,et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.
[33] B. Gazzard,et al. No change to HIV-1 latency with valproate therapy. , 2006, AIDS.
[34] E. De Clercq,et al. Potent and Selective Inhibition of HIV and SIV by Prostratin Interacting with Viral Entry , 2003, Antiviral chemistry & chemotherapy.
[35] A. Burny,et al. HIV‐1 Tat transcriptional activity is regulated by acetylation , 1999, The EMBO journal.
[36] M. Hezareh. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. , 2005, Drug news & perspectives.
[37] D. Olive,et al. Triggering CD 28 molecules synergize with CD 2 (T11.1 and T11,2)‐mediated T cell activation , 1988, European journal of immunology.
[38] D. Margolis,et al. Targeted Derepression of the Human Immunodeficiency Virus Type 1 Long Terminal Repeat by Pyrrole-Imidazole Polyamides , 2002, Journal of Virology.
[39] K. Gustafson,et al. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). , 1997, Antiviral research.
[40] M. Dybul,et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Apetrei,et al. HIV genetic diversity: biological and public health consequences. , 2007, Current HIV research.
[42] P. Cox,et al. Variability in Content of the Anti-AIDS Drug Candidate Prostratin in Samoan Populations of Homalanthus nutans , 2008, Journal of natural products.
[43] P. Wender,et al. Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV , 2008, Science.
[44] E. Verdin. DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1 , 1991, Journal of virology.
[45] J. Justement,et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.
[46] M. Guenther,et al. Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.
[47] P. Marks,et al. Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.
[48] F. Dequiedt,et al. Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.
[49] A. Rice,et al. Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells , 2006, Retrovirology.
[50] A. Skalka,et al. High-Frequency Epigenetic Repression and Silencing of Retroviruses Can Be Antagonized by Histone Deacetylase Inhibitors and Transcriptional Activators, but Uniform Reactivation in Cell Clones Is Restricted by Additional Mechanisms , 2007, Journal of Virology.
[51] Y. Korin,et al. Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.
[52] Cheryl Jennings,et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.
[53] D. Hamer,et al. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. , 2004, AIDS research and human retroviruses.
[54] J. Piette,et al. Crucial Role of the Amino-Terminal Tyrosine Residue 42 and the Carboxyl-Terminal PEST Domain of IκBα in NF-κB Activation by an Oxidative Stress1 , 2000, The Journal of Immunology.
[55] T. Mizutani,et al. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines , 2006, Oncogene.
[56] Yassine Taoufik,et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.
[57] S. Brusilow,et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. , 1995, Blood.
[58] Richard D Moore,et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. , 2007, The Journal of infectious diseases.
[59] D. Costagliola,et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir , 2008, AIDS.
[60] S. Brusilow,et al. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. , 1994, Blood.
[61] E. Verdin,et al. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. , 1998, Journal of immunology.
[62] B. Berkhout,et al. Functional Differences between the Long Terminal Repeat Transcriptional Promoters of Human Immunodeficiency Virus Type 1 Subtypes A through G , 2000, Journal of Virology.
[63] Ben Berkhout,et al. Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-κB and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic Strategies , 2002, Journal of Virology.
[64] D. Margolis. Confronting proviral HIV infection , 2007, Current HIV/AIDS reports.
[65] A. Burny,et al. Potentiation of Tumor Necrosis Factor-Induced NF-κB Activation by Deacetylase Inhibitors Is Associated with a Delayed Cytoplasmic Reappearance of IκBα , 2003, Molecular and Cellular Biology.
[66] R. Reeves,et al. Recruitment of SWI/SNF to the Human Immunodeficiency Virus Type 1 Promoter , 2004, Molecular and Cellular Biology.
[67] M. Foti,et al. Mechanisms of HIV Receptor and Co-Receptor Down-Regulation by Prostratin: Role of Conventional and Novel PKC Isoforms , 2004, Antiviral chemistry & chemotherapy.
[68] Tom Misteli,et al. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[69] R. Greil,et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia , 2002, British journal of haematology.
[70] F. Buonaguro,et al. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.
[71] E. Verdin,et al. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. , 1997, Genes & development.
[72] R. Siliciano,et al. The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.
[73] J. Coffin,et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells , 2008, AIDS.
[74] M. Giacca,et al. Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.
[75] T. Okamoto,et al. Transcriptional Repression of Human Immunodeficiency Virus Type 1 by AP-4* , 2006, Journal of Biological Chemistry.
[76] Richard Pazdur,et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.
[77] Lawrence Corey,et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. , 2007, The Journal of infectious diseases.
[78] Z. Szallasi,et al. A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. , 1992, Journal of medicinal chemistry.
[79] Arthur Weiss,et al. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. , 1984, Journal of immunology.
[80] C. Johannessen,et al. Mechanisms of action of valproate: a commentatory , 2000, Neurochemistry International.
[81] E. Verdin,et al. NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.
[82] J. McCune,et al. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells* , 2009, Journal of Biological Chemistry.
[83] M. Duvic,et al. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.
[84] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[85] Amy S. Espeseth,et al. c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter , 2007, Journal of Virology.
[86] A. Jordan,et al. The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.
[87] D. Hamer,et al. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. , 2003, Antiviral research.
[88] D. Margolis,et al. Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.
[89] O. Bagasra,et al. HIV-1 latency due to the site of proviral integration. , 1993, Virology.
[90] Amy S. Espeseth,et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. , 2009, AIDS research and human retroviruses.
[91] D. Olive,et al. Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[92] D. Margolis,et al. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. , 2008, The Journal of infectious diseases.
[93] A. Burny,et al. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. , 2008, Trends in biochemical sciences.
[94] C. Van Lint,et al. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. , 1993, The EMBO journal.